MARKET

ACHL

ACHL

Achilles Therapeutics Plc
NASDAQ
0.8155
+0.0010
+0.12%
Opening 13:50 04/18 EDT
OPEN
0.8200
PREV CLOSE
0.8145
HIGH
0.8200
LOW
0.8000
VOLUME
128.33K
TURNOVER
0
52 WEEK HIGH
1.760
52 WEEK LOW
0.7402
MARKET CAP
32.52M
P/E (TTM)
-0.4679
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACHL last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ACHL last week (0401-0405)?
Weekly Report · 04/08 09:10
Piper downgrades Achilles to neutral, cites latest data
Healthcare Piper downgrades Achilles to neutral, cites latest data from its precision T cell therapy. Achilles released data from the CHIRON and THETIS studies on Thursday. Piper lowered its price target for the stock to $2 from $8, citing the latest data.
Seeking Alpha · 04/05 14:44
Achilles Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/05 10:47
Achilles Therapeutics Price Target Cut to $6.00/Share From $11.00 by Chardan Capital
Dow Jones · 04/05 10:47
Achilles Therapeutics Cut to Neutral From Overweight by Piper Sandler
Dow Jones · 04/05 10:43
Achilles Therapeutics Price Target Cut to $2.00/Share From $8.00 by Piper Sandler
Dow Jones · 04/05 10:43
Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $6
Benzinga · 04/05 10:38
More
About ACHL
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.

Webull offers Achilles Therapeutics PLC (ADR) stock information, including NASDAQ: ACHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHL stock methods without spending real money on the virtual paper trading platform.